Hideki Suganami

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto et al. · Cardiovascular Diabetology · 2014 · 216 citations · Full text

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Shun Ishibashi, Shizuya Yamashita, Hidenori Arai et al. · Atherosclerosis · 2016 · 208 citations · Full text

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda et al. · Alimentary Pharmacology & Therapeutics · 2021 · 192 citations · Full text

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Shun Ishibashi, Hidenori Arai, Koutaro Yokote et al. · Journal of clinical lipidology · 2017 · 182 citations · Full text

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Eiichi Araki, Shizuya Yamashita, Hidenori Arai et al. · Diabetes Care · 2018 · 154 citations · Full text